ServiceNow's CFO highlighted that while GenAI investments may not yield quick returns, they are expected to transform industries long-term, particularly in pharmaceuticals.
Mastantuono elaborated on AI's potential in pharma, stating that by reducing time to market from 6.6 years to potentially 5.6 years, it could save billions.
Zelnick pointed out the challenges companies face in justifying the ROI for generative AI, citing difficulties in committing spend offsets and savings.
In addressing the bubble concern, Mastantuono acknowledged that generative AI spending could be inflated but stressed the importance of viewing it as a long-term evolution.
[
Collection
]
[
|
...
]